CURIS, INC. (NASDAQ:CRIS) Files An 8-K Other Events

CURIS, INC. (NASDAQ:CRIS) Files An 8-K Other Events

Story continues below

Item8.01

Other Events

From time to time, we conduct meetings with third parties in
which we utilize a corporate slide presentation. A copy of our
current corporate slide presentation, dated June 2017, is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.

Item9.01. Financial Statements and Exhibits
(d) The exhibit to this Current Report on Form 8-K is listed in
the Exhibit Index attached hereto.


About CURIS, INC. (NASDAQ:CRIS)

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

An ad to help with our costs